CA2140653A1 - Inhibiteurs de la proteine kinase et composes connexes combines avec le taxol - Google Patents

Inhibiteurs de la proteine kinase et composes connexes combines avec le taxol

Info

Publication number: CA2140653A1
Authority: CA; Canada
Prior art keywords: alkyl; compound; tumors; taxol; alpha
Prior art date: 1992-08-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002140653A

Other languages

English (en)

Inventor

Irene Abraham

Paul A. Aristoff

Harvey I. Skulnick

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacia and Upjohn Co

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-12

Filing date

1993-07-30

Publication date

1994-03-03

1993-07-30 Application filed by Individual filed Critical Individual

1994-03-03 Publication of CA2140653A1 publication Critical patent/CA2140653A1/fr

Status Abandoned legal-status Critical Current

Links

RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 116
150000001875 compounds Chemical class 0.000 title claims abstract description 88
229960001592 paclitaxel Drugs 0.000 title claims description 113
229930012538 Paclitaxel Natural products 0.000 title claims description 112
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract description 6
239000003909 protein kinase inhibitor Substances 0.000 title abstract description 6
-1 hexyl ester Chemical class 0.000 claims description 29
239000003814 drug Substances 0.000 claims description 23
KOZFSFOOLUUIGY-SOLYNIJKSA-N K-252a Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@](C(=O)OC)(O)[C@]4(C)O1 KOZFSFOOLUUIGY-SOLYNIJKSA-N 0.000 claims description 19
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 16
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
230000012010 growth Effects 0.000 claims description 11
206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
125000000753 cycloalkyl group Chemical group 0.000 claims description 10
229960001603 tamoxifen Drugs 0.000 claims description 8
206010006187 Breast cancer Diseases 0.000 claims description 7
208000032839 leukemia Diseases 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
230000000069 prophylactic effect Effects 0.000 claims description 7
BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 claims description 6
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 claims description 5
VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 claims description 5
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical group C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 claims description 4
229940046836 anti-estrogen Drugs 0.000 claims description 4
230000001833 anti-estrogenic effect Effects 0.000 claims description 4
239000000328 estrogen antagonist Substances 0.000 claims description 4
208000037841 lung tumor Diseases 0.000 claims description 4
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 3
CLLFEJLEDNXZNR-UUOKFMHZSA-N (4ar,6r,7r,7as)-6-(6-amino-8-chloropurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Cl CLLFEJLEDNXZNR-UUOKFMHZSA-N 0.000 claims description 3
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 3
229930194791 calphostin Natural products 0.000 claims description 3
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 3
229960001076 chlorpromazine Drugs 0.000 claims description 3
208000029742 colonic neoplasm Diseases 0.000 claims description 3
HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims description 3
208000014829 head and neck neoplasm Diseases 0.000 claims description 3
229960000905 indomethacin Drugs 0.000 claims description 3
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 3
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims description 3
CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims description 3
229960001722 verapamil Drugs 0.000 claims description 3
108010093965 Polymyxin B Proteins 0.000 claims description 2
108010040201 Polymyxins Proteins 0.000 claims description 2
229940009456 adriamycin Drugs 0.000 claims description 2
GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical compound C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
229920000024 polymyxin B Polymers 0.000 claims description 2
229960005266 polymyxin b Drugs 0.000 claims description 2
241000282412 Homo Species 0.000 claims 6
241000124008 Mammalia Species 0.000 claims 6
201000001441 melanoma Diseases 0.000 claims 6
230000001225 therapeutic effect Effects 0.000 claims 6
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 5
206010017758 gastric cancer Diseases 0.000 claims 4
201000010536 head and neck cancer Diseases 0.000 claims 4
201000005202 lung cancer Diseases 0.000 claims 4
208000029565 malignant colon neoplasm Diseases 0.000 claims 4
238000004519 manufacturing process Methods 0.000 claims 4
230000002265 prevention Effects 0.000 claims 4
125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 2
MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims 2
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims 2
206010061968 Gastric neoplasm Diseases 0.000 claims 2
ZQHYKVKNPWDQSL-KNXBSLHKSA-N phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 claims 2
229960000897 phenazocine Drugs 0.000 claims 2
ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims 2
229960002324 trifluoperazine Drugs 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 29
201000011510 cancer Diseases 0.000 abstract description 14
230000002195 synergetic effect Effects 0.000 abstract description 5
230000015572 biosynthetic process Effects 0.000 abstract description 2
238000003786 synthesis reaction Methods 0.000 abstract description 2
230000002301 combined effect Effects 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
230000000694 effects Effects 0.000 description 36
241000699670 Mus sp. Species 0.000 description 19
210000004027 cell Anatomy 0.000 description 19
229940079593 drug Drugs 0.000 description 19
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
125000000217 alkyl group Chemical group 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 16
238000000034 method Methods 0.000 description 16
238000004128 high performance liquid chromatography Methods 0.000 description 15
239000007787 solid Substances 0.000 description 15
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 10
239000002253 acid Substances 0.000 description 9
238000004949 mass spectrometry Methods 0.000 description 9
150000002500 ions Chemical class 0.000 description 8
230000014759 maintenance of location Effects 0.000 description 8
238000003756 stirring Methods 0.000 description 8
239000002246 antineoplastic agent Substances 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
231100000419 toxicity Toxicity 0.000 description 6
230000001988 toxicity Effects 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000001727 in vivo Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
229940041181 antineoplastic drug Drugs 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000007858 starting material Substances 0.000 description 4
229940063683 taxotere Drugs 0.000 description 4
206010033128 Ovarian cancer Diseases 0.000 description 3
241001116500 Taxus Species 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
239000000463 material Substances 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
CETWDUZRCINIHU-UHFFFAOYSA-N 2-heptanol Chemical compound CCCCCC(C)O CETWDUZRCINIHU-UHFFFAOYSA-N 0.000 description 2
NGDNVOAEIVQRFH-UHFFFAOYSA-N 2-nonanol Chemical compound CCCCCCCC(C)O NGDNVOAEIVQRFH-UHFFFAOYSA-N 0.000 description 2
RZKSECIXORKHQS-UHFFFAOYSA-N Heptan-3-ol Chemical compound CCCCC(O)CC RZKSECIXORKHQS-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
229940044684 anti-microtubule agent Drugs 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000007541 cellular toxicity Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
229960001231 choline Drugs 0.000 description 2
238000011278 co-treatment Methods 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical compound C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
150000002825 nitriles Chemical class 0.000 description 2
ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 description 1
QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
201000000274 Carcinosarcoma Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 1
108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
241000219492 Quercus Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
208000006268 Sarcoma 180 Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000287181 Sturnus vulgaris Species 0.000 description 1
241000202349 Taxus brevifolia Species 0.000 description 1
240000006365 Vitis vinifera Species 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
QLZHNIAADXEJJP-UHFFFAOYSA-L dioxido-oxo-phenyl-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)C1=CC=CC=C1 QLZHNIAADXEJJP-UHFFFAOYSA-L 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229960000555 fenyramidol Drugs 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229960005544 indolocarbazole Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000009521 phase II clinical trial Methods 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
150000003254 radicals Chemical group 0.000 description 1
238000011160 research Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
150000003410 sphingosines Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

CA002140653A 1992-08-12 1993-07-30 Inhibiteurs de la proteine kinase et composes connexes combines avec le taxol Abandoned CA2140653A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92919992A	1992-08-12	1992-08-12
US929,199		1992-08-12

Publications (1)

Publication Number	Publication Date
CA2140653A1 true CA2140653A1 (fr)	1994-03-03

Family

ID=25457472

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002140653A Abandoned CA2140653A1 (fr)	1992-08-12	1993-07-30	Inhibiteurs de la proteine kinase et composes connexes combines avec le taxol

Country Status (6)

Country	Link
EP (1)	EP0655066A1 (fr)
JP (1)	JPH08500112A (fr)
KR (1)	KR950702994A (fr)
AU (1)	AU4787693A (fr)
CA (1)	CA2140653A1 (fr)
WO (1)	WO1994004541A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6479526B1 (en)	1995-04-12	2002-11-12	The Procter & Gamble Company	Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en)	1995-04-12	2001-07-17	The Proctor & Gamble Company	Methods of treating cancer with benzimidazoles
US6265427B1 (en)	1995-06-07	2001-07-24	The Proctor & Gamble Company	Pharmaceutical composition for the method of treating leukemia
US6274576B1 (en)	1995-06-27	2001-08-14	The Henry Jackson Foundation For The Advancement Of Military Medicine	Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
JPH11509193A (ja) *	1995-06-27	1999-08-17	ヘンリーエム．ジャクソンファウンデーションフォーザアドバンスメントオブミリタリーメディシン	細胞傷害を増強するための細胞周期動力学の動的遅延方法
WO1997005140A1 (fr) *	1995-07-31	1997-02-13	Novartis Ag	Composes de trindene
US5900429A (en)	1997-01-28	1999-05-04	The Procter & Gamble Company	Method for inhibiting the growth of cancers
US6506783B1 (en)	1997-05-16	2003-01-14	The Procter & Gamble Company	Cancer treatments and pharmaceutical compositions therefor
ATE251624T1 (de) *	1998-03-13	2003-10-15	Univ British Columbia	Granulatimide-derivate zur behandlung von krebs
CA2245029A1 (fr)	1998-03-13	1999-09-13	University Of British Columbia	Composes granulatimide en tant qu'inhibiteurs de controle g2
US6245789B1 (en)	1998-05-19	2001-06-12	The Procter & Gamble Company	HIV and viral treatment
US6013646A (en) *	1998-07-02	2000-01-11	Bayer Corporation	Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6235776B1 (en) *	1998-11-12	2001-05-22	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (fr)	1999-01-13	2011-12-28	Bayer HealthCare LLC	DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
US7820718B1 (en) *	1999-04-07	2010-10-26	Roger Williams Hospital	Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
GB9915069D0 (en) *	1999-06-28	1999-08-25	Inst Biomar Sa	New indolocarbazole alkaloids from a marine actinomycete
US6472385B1 (en) *	1999-08-09	2002-10-29	Trustees Of Darmouth College	Compositions and methods to enhance cancer chemotherapy in p53 defective tumors
US6423734B1 (en)	1999-08-13	2002-07-23	The Procter & Gamble Company	Method of preventing cancer
US6608096B1 (en)	2000-09-26	2003-08-19	University Of Arizona Foundation	Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) *	2000-09-26	2002-06-18	The Procter & Gamble Company	Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en)	2000-09-26	2002-04-30	The Procter & Gamble Company	Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en)	2000-09-26	2002-10-08	The Procter & Gamble Company	Compounds and methods for use thereof in the treatment of cancer or viral infections
US6548531B2 (en) *	2001-02-09	2003-04-15	Hoffmann-La Roche Inc.	Method for cancer therapy
US20020169154A1 (en) *	2001-04-04	2002-11-14	Cephalon, Inc.	Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
SI1478358T1 (sl)	2002-02-11	2013-09-30	Bayer Healthcare Llc	Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
IL149404A0 (en) *	2002-04-29	2002-11-10	Yissum Res Dev Co	METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
WO2004026319A2 (fr) *	2002-09-17	2004-04-01	Centre National De La Recherche Scientifique	Compositions pharmaceutiques utilisees pour le traitement de cancers
EP1636585B2 (fr)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl-urees presentant une activite d'inhibition des kinases
US20060210553A1 (en) *	2003-07-23	2006-09-21	Creabilis Therapeutics S.R.L.	Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excesssive cell proliferation
CA2479696A1 (fr)	2003-11-11	2005-05-11	Amadeo Parissenti	Utilisation de la calphostine-c pour traiter les cellules tumorales sensibles aux medicaments
KR20080046161A (ko) *	2005-08-09	2008-05-26	요하네스 구텐베르크-유니버시타트 마인츠	비-소세포 폐암의 치료를 위한 스타우로스포린 유도체
KR102271848B1 (ko) *	2013-11-01	2021-07-01	피트니 파마슈티컬스 피티와이 리미티드	암 치료용 약학적 배합물
KR102491180B1 (ko)	2017-04-27	2023-01-20	파르마 마르 에스.에이.	항종양 화합물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62155284A (ja) *	1985-12-27	1987-07-10	Kyowa Hakko Kogyo Co Ltd	生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) *	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
US4923986A (en) *	1987-03-09	1990-05-08	Kyowa Hakko Kogyo Co., Ltd.	Derivatives of physiologically active substance K-252
JPH07113027B2 (ja) *	1987-12-24	1995-12-06	協和醗酵工業株式会社	Ｋ−２５２誘導体

1993
- 1993-07-30 CA CA002140653A patent/CA2140653A1/fr not_active Abandoned
- 1993-07-30 EP EP93918422A patent/EP0655066A1/fr not_active Withdrawn
- 1993-07-30 KR KR1019950700489A patent/KR950702994A/ko not_active Withdrawn
- 1993-07-30 WO PCT/US1993/007054 patent/WO1994004541A2/fr not_active Ceased
- 1993-07-30 AU AU47876/93A patent/AU4787693A/en not_active Abandoned
- 1993-07-30 JP JP6506283A patent/JPH08500112A/ja active Pending

Also Published As

Publication number	Publication date
EP0655066A1 (fr)	1995-05-31
KR950702994A (ko)	1995-08-23
AU4787693A (en)	1994-03-15
JPH08500112A (ja)	1996-01-09
WO1994004541A2 (fr)	1994-03-03
WO1994004541A3 (fr)	1994-06-09

Legal Events

Date	Code	Title	Description
1998-07-30	FZDE	Dead

Publication	Publication Date	Title
CA2140653A1 (fr)	1994-03-03	Inhibiteurs de la proteine kinase et composes connexes combines avec le taxol
KR100483256B1 (ko)	2005-04-15	젬시타빈 유도체
IL89503A (en)	1994-02-27	Taxol derivatives, pharmaceutical compositions containing the same and process for the preparation thereof
JP5087052B2 (ja)	2012-11-28	改良された治療剤
KR20100102092A (ko)	2010-09-20	아자시티딘 유사체 및 이들의 용도
KR20020082458A (ko)	2002-10-31	탁산 프로드럭
TWI306028B (en)	2009-02-11	A combination comprising combretastatin and anticancer agnets
JP4540986B2 (ja)	2010-09-08	ワートマニン類似体およびそれらを用いる方法
CA2522980A1 (fr)	2004-11-04	Derives de wortmannine solubles dans l'eau
AU2002330029A1 (en)	2003-06-05	Wortmannin analogs and methods of using same
HU217551B (hu)	2000-02-28	6[(2-Hidroxi-etil)-amino-alkil]-5,11-dioxo-5,6-dihidro-11H-indén[1,2-c]izokinolin-származékok, valamint eljárás előállításukra, továbbá hatóanyagként e vegyületeket tartalmazó gyógyászati készítmények
RU2194711C2 (ru)	2002-12-20	Производные гемцитабина
Lenaz et al.	1974	Biologic Activity of Some Adriamycin (NSC-123127) Derivatives 1, 2
CN101787066B (zh)	2013-07-31	阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
KR102916585B1 (ko)	2026-01-23	핵 유전자 손상을 최소화한 암 치료를 위한 미토콘드리아 표적 변형 항생제 화합물 및 이를 포함하는 항암 약학 조성물
JP2002535276A (ja)	2002-10-22	４−デメチルペンクロメジンのアシル誘導体、その使用及び調製
WO2004063211A1 (fr)	2004-07-29	Derives hydrocarbones de paclitaxel et de docetaxel, procede de production et utilisation desdits derives
EP1607091A1 (fr)	2005-12-21	Agent anti-virus de l'hepatite c et agent anti-vih
WO2011113175A1 (fr)	2011-09-22	Dérivés de promédicament de cytarabine et utilisation associée dans la résistance contre le cancer ou une tumeur
RU2200157C2 (ru)	2003-03-10	Пиридинкарбоксамидины, способ их получения и фармацевтическая композиция на их основе
US5914321A (en)	1999-06-22	Antitumoral method by administration of partricin derivatives
TW202539625A (zh)	2025-10-16	包括９－順式視黃酸及單醣之綴合化合物
ES2307253T3 (es)	2008-11-16	Analogos de la wortmannina y procedimientos de uso de los mismos.
RU2487883C2 (ru)	2013-07-20	Аналоги азацитидина и их применение
Driscoll et al.	1977	Antineoplastic Agents